Enhancing the blood circulation of radiopharmaceuticals by modifying small molecules with an entity that interacts with serum albumin in a non-covalent manner was identified as an effective means to increase tumor uptake and, thus, deliver a sufficient radiation dose to achieve a treatment response [15,16]. This evidence concerns the gene ALB and neoplasm.